| Name | Title | Contact Details |
|---|
Kolltan Pharmaceuticals is a private company founded in 2007 that is developing novel monoclonal antibody (mAb) drugs targeting receptor tyrosine kinases (RTKs). Kolltan's primary targets derive from seminal discoveries made in the laboratory of Dr. Joseph Schlessinger, Chairman of the Department of Pharmacology at the Yale School of Medicine, and in Kolltan’s laboratories. Dr. Schlessinger's laboratory has characterized a novel molecular mechanism underlying activation of RTKs providing, for the first time, a clear molecular explanation — at atomic resolution — for the oncogenic activity of mutations that have been identified in a variety of human cancers.
Founded in 1984 as a physician-founded and guided health plan, CDPHP and its affiliates currently serve members in 24 counties throughout New York with a full family of products.
Halfpenny Technologies, Inc. provides clinical labs, hospitals, accountable care organizations (ACOs), health plans, health information exchanges (HIEs) and EHR vendors with a cloud-based, secure, scalable and vendor-neutral clinical data exchange platform designed to optimize patient care coordination while reducing waste. We have a long-standing, proven track record of providing advanced features, rapid implementation, reliable technology infrastructure and LOINC mapping that enables laboratories and hospitals to win new accounts and improve service to existing clients
Diabetes Centers of America is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Patient-Centered Outcomes Research Institute is a Washington, DC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.